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1ABSTRACT
Analysis of neurocognitive and cortical thinning patterns between early onset 
and late onset Parkinson's disease dementia
Younggwang Kim
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Phil Hyu Lee)
Cognitive dysfunction in Parkinson’s disease (PD) is one of the most 
disabling features and occurs mainly in old age. Although aging is a risk 
factor of dementia in PD, the early onset form of Parkinson’s disease 
dementia (PDD) had not been researched. The present study included 116 
patients with PDD and 121 patients with normal cognition, The subjects 
were divided into two groups based on a cutoff value of 70 years; 39 patients 
with onset age younger than 70 years (Early-onset PDD, EOPDD) and 77 
patients with onset after 70 years of age (Late-onset PDD, LOPDD). All of 
these patients were assessed with a neuropsychological battery. Among the 
patients, 65 underwent three-dimensional T1-weighted MRI scans and 
analyses of cortical thickness. In addition, volumetry of substantia 
innominata (SI) was performed. The effects of diagnosis and age and their 
interaction on neuropsychological tests, cortical thickness, and volume of SI 
were assessed using analysis of covariance. The EOPDD group exhibited 
poorer performance in backward span (p=0.011) and visual recognition tests 
(p=0.002) after adjusting for the effect of aging. In cortical thickness 
2analysis, the LOPDD group showed widespread cortical thickness. After 
adjusting for age, the EOPDD group exhibited greater cortical thinning in the 
left anterior cingulate gyrus and right mesial temporal area, with a lower 
threshold of uncorrected p<0.001. The normalized SI volume was decreased 
in the EOPDD group after adjusting for aging effects in volumetric analysis. 
Our data suggest that EOPDD may be a distinct phenotype different from 
LOPDD. EOPDD had a greater pathological burden in key structures 
responsible for PD-related cognitive decline, whereas LOPDD had a 
widespread pathological burden related to aging.
----------------------------------------------------------------------------------------
Key words : Parkinson's disease dementia, Age at onset, Neuropsychological 
test, Cortical thickness
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I. INTRODUCTION
Cognitive dysfunction in Parkinson’s disease (PD) is one of the most disabling non-
motor features leading to poorer performances of daily living and increase in 
caregiver burden. Clinical risk factors and neuroimaging predictor for ongoing 
cognitive decline in patients with PD have been suggested. Neuropsychological 
predictions of dementia in PD (PDD) in longitudinal studies suggested that 
cognitive performance associated with posterior cortical areas, such as semantic 
fluency and visuoconstructional ability seems to be an important determinant for 
ongoing cognitive decline of PD,1 although frontal executive functions are also 
considered a significant predictor of PDD.2 Additionally, poor performance at 
baseline is an independent predictor of cognitive decline in PD.3 In aspects of 
functional neuroimaging, the status of cerebral glucose metabolism in posterior 
visual association cortical areas and posterior cingulate areas was a significant 
predictor of dementia in patients with PD.4 Moreover, the cholinergic system arising 
from the nucleus basalis of Meynert located in the substantia innominata (SI) of the 
basal forebrain was suggested as an important neural system responsible for 
cognitive dysfunctions and ongoing cognitive decline in PD patients.5,6
Ample evidence has showed that aging is the most important risk factor of
development of PDD7,8 and thus, there has been amount of efforts to evaluate
4chronological changes of PD pathologies in PD patients. It was well known that 
early-onset PD patients showed slower disease progression and lower rates of 
dementia.9 However, one longitudinal study showed age itself, rather than age at 
motor symptom onset is associated with incident dementia in subjects with PD.10
One prospective study also showed a relationship between age and cognitive decline,
with particular susceptibility above 70 years of age.1 Another clinico-pathologic 
study comparing PD patient groups showed that PD patients reached a common 
pathological endpoint at a similar average age irrespective of age of onset or disease 
duration, suggesting that aging might accelerate progression after the age of 70 
years.11
However, despite lower incidence, early onset PD patient experienced dementia
like other neurodegenerative disease. In Alzheimer’s disease, ample evidence 
pointed out that early-onset AD and late onset AD had different phenotype. Early-
onset AD presented with more diverse cognitive impairment,12 faster cognitive 
decline,13 more temporo-parietal defects in perfusion,14 more cortical thinning15 and 
more pathologic burdens.16 These findings suggest the causal mechanisms
underlying the two forms of disease might be different, and thus therapeutic 
strategies should be specifically considered for early-onset AD. In this regard, it is 
reasonable to postulate that clinical and pathological phenotype in patients with 
PDD might differ depending on onset age. However, early onset form of PDD had 
not been focused yet clinically.
In the present study, we analyzed neuropsychological profiles and radiological 
patterns of cortical thinning and measured the SI volumes in patients with early-
onset and late-onset PDD to examine whether patients with PDD represent clinical 
and radiological heterogeneity depending on age at onset. 
5II. MATERIALS AND METHODS
1. Subjects
The study included 116 patients with PDD recruited from the Movement Disorders 
and Dementia outpatient clinic at Yonsei University Severance Hospital from March 
2007 to December 2014. PD was diagnosed according to the clinical diagnostic 
criteria of the UK PD Society Brain Bank.17 PDD was diagnosed based on the 
Movement Disorder Society consensus criteria for dementia associated with PD.18
To ensure sufficient clinical diagnosis of PDD, we enrolled patients showing 
decreased dopamine transporter uptake in the posterior putamen on [18F]FP-CIT 
PET scans. Motor symptoms were assessed using the Unified PD Rating Scale Part 
Ⅲ (UPDRS-Ⅲ).
Depending on the age at PDD diagnosis, the patients were divided into early-onset 
PDD (EOPDD < 70 years of age, n= 39) and late-onset PDD (LOPDD ≥ 70 years of 
age, n=77). Each patient underwent history taking, laboratory examinations, 
physical and neurological examinations and conventional brain magnetic resonance 
imaging (MRI) scans. Disease duration and memory complaints in each patient 
were based on interviews with patients and caregivers living with patients. We also 
used the caregiver-based structured interview of the Neuropsychiatric Inventory 
(NPI),19 which was administered by a trained neuropsychologist. History of 
hypertension was defined as prior physician-diagnosed hypertension with or without 
the use of antihypertensive agents, and history of diabetes or dyslipidemia was 
defined based on self-report or the use of hypoglycemic or lipid-lowering agents.
All patients participated in the Seoul Neuropsychological Screening Battery (SNSB),
consisting of the following cognitive subsets: attention (forward and backward digit 
span), language and related functions (Korean version of the Boston Naming Test 
and calculation), visuospatial function (Rey Complex Figure Test; RCFT), verbal 
memory (three-word registration and recall and the Seoul Verbal Learning Test), 
visual memory (RCFT, immediate recall, 20-minute delayed recall, and recognition), 
and frontal/executive function (contrasting program, go-no-go test, phonemic and 
6semantic fluency test, and Stroop test). The scores of these quantifiable cognitive 
tests were classified as abnormal when they were below the 16th percentile of the 
norms for the age-, gender- and education-matched normal subjects. 
We recruited 121 healthy age- and sex-matched normal controls who had no history 
of neurological disease and no abnormalities on neurologic examinations. The 
normal controls exhibited no objective cognitive dysfunction on the mini-mental 
state examination (MMSE) and neuropsychological tests (SNSB). The normal 
controls were divided into the young control group (< 70 years of age) and the old 
control group (≥ 70 years of age) and were compared with the respective age-
matched PDD group; 49 were allotted to the young controls and 72 to the old 
controls.
Among study subjects, three-dimensional T1-weighted MRI scans used for cortical 
thickness analysis were available in 65 patients with PDD. Of these 65 patients, 25 
were classified as EOPDD and 40 patients as LOPDD. We excluded patients with 
focal neurological deficits, evidence of focal brain lesions, diffuse white matter 
intensities, multiple lacunae in the basal ganglia based on MRI, or other past 
medical comorbidities that could contribute to cognitive decline. Possible medical 
comorbidities were excluded using laboratory tests, including thyroid function test, 
vitamin B12 and folic acid levels, and VDRL test.
This study was approved by the Yonsei University Severance Hospital ethical 
standards committee on human experimentation for experiments using human 
subjects. Written informed consent was obtained from all subjects participating in 
this study.
2. MRI acquisition
All scans were acquired using a Philips 3.0-T scanner (Philips Intera; Philips 
Medical System, Best, The Netherlands) with a SENSE head coil (SENSE factor=2).
A high-resolution T1-weighted MRI volume data set was obtained from all subjects 
using a 3D T1-TFE sequence configured with the following acquisition parameters: 
axial acquisition with a 224 × 256 matrix; 256 × 256 reconstructed matrix with 182 
7slices; 220 mm field of view; 0.98 × 0.98 × 1.2 mm3 voxels; TE, 4.6 ms; TR, 9.6 
ms; flip angle, 8°; slice gap, 0 mm.
3. Image processing for cortical thickness
We corrected intensity inhomogeneity caused by magnetic field inhomogeneity by
varying the signal intensity slowly over the image. The N3 algorithm was used to 
correct images for intensity non-uniformities resulting from inhomogeneities in the 
magnetic field.20 Skull stripping was performed using a Brain Extraction Tool 
(BET) with a deformable model fitted to the brain surface and optimized
parameters.21 Each brain was transformed separately into a standardized stereotaxic 
space (an ICBM 152 template) and resampled on a 1 mm3 voxel grid to account for 
inter-individual differences in absolute brain size.22 An artificial neural network 
classifier was applied to identify gray matter (GM), white matter (WM), and 
cerebrospinal fluid (CSF).23 Partial volume level and MRI intensity mixing at the 
tissue interfaces due to the finite resolution of the imaging device were estimated 
and corrected using a trimmed minimum covariance determinant method.24 A 
cortical surface was extracted automatically from each MR volume using the 
Constrained Laplacian-based Automated Segmentation with Proximities (CLASP) 
algorithm.25 Cortical thickness was defined as the Euclidean distance between 
linked vertices or the inner and outer surfaces. The inner surface was defined by the 
WM/GM boundary surfaces and the outer surface by GM/CSF boundary surfaces.
Diffusion smoothing, which generalizes Gaussian kernel smoothing, with 20-mm 
full width half maximum (FWHM) was used to increase the signal to noise ratio and 
adequately detect population changes. To assess group differences in cortical 
thickness, a general linear model was constructed with age, sex, and intracranial 
volume as independent variables and each of the vertices of thickness as a 
dependent variable. For multiple comparisons, the results were thresholded at a
false discovery rate (FDR)-corrected p-value of 0.05 and cluster of 100. In addition, 
the effect of diagnosis (PDD versus control), age (< 70 years versus ≥ 70 years), and 
their interaction with cortical thinning was assessed using analysis of covariance 
8(ANCOVA) with a threshold of uncorrected p<0.001 and cluster of 100, controlling 
for educational level, hypertension, diabetes mellitus, and hyperlipidemia.
4. Volumetric determination of SI
The analysis was performed using Statistical Parametric Mapping software (SPM8, 
Wellcome Department of Imaging Neuroscience, London, UK, available at 
http://www.ﬁl.ion.ucl.ac.uk/spm). Each structural MRI scan was bias-corrected, 
segmented into SPM default tissue probability maps, and then normalized with 
VBM8 DARTEL templates for registration to MNI space using linear (12-parameter 
affine) and nonlinear transformations within a unified model. According to a 
previous study,26 the ROI of SI was defined for the left and right hemispheres based 
on the location of the anterior commissure, which forms the boundary of the 
superior part of the end of the anterior third of the substantia innominata. The ROI 
extended 25 mm lateral from the midline, 13 mm ventral from the superior edge of 
the anterior commissure at the midline, and 3 mm anterior and 9 mm posterior from 
the middle of the anterior commissure (Figure 1). The masks were created using the 
WFU PickAtlas 2.4 software,27 and volumetry of GM within a selected ROI was 
performed automatically. The total SI volume calculated included both the right and 
left hemispheres. To correct for individual brain size, volumes were normalized by 
dividing by total intracranial volume derived from the masks covering the entire 
brain. Normalized SI volume was deﬁned by the following formula: total SI volume 
(mL)/total intracranial volume (mL) X 10,000.
5. Statistical analysis
The c2 and Mann-Whitney U tests were used for categorical and continuous 
variables, respectively. The effect of diagnosis (PDD versus control) and age (<70 
versus ≥70), and their interaction on neuropsychological tests and volumes of SI 
were assessed with analysis of covariance (ANCOVA), controlling for educational
years, hypertension, diabetes mellitus, and hyperlipidemia. The significance of the 
interaction was tested in a full factorial model including the two main effects of 
9diagnosis and age, and their interaction. As both PDD groups had test scores poorer 
and brain volumes lower than the pertinent control group, significance of the 
interaction denoted a relatively poorer performance or relatively lower volumes in 
one of the two patient groups. Statistical analyses were performed using 
commercially available software (SPSS, version 18.0), and a two- tailed P < 0.05 
was considered significant. 
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Figure 1. Mask image for ROI of substantia innominata. A region of interest is 
placed on the PD scan in MNI space starting at the middle (anterior–posterior) 
rostral level of the anterior commissure in the midline and extending 25, 13 and 12 
mm in x, y and z directions, respectively.
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III. RESULTS
1. Demographic characteristics of the EOPDD and LOPDD
The demographic characteristics of patients with PDD are shown in Table 1. Mean 
age at onset was 64.6 years in EOPDD and 75.5 years in LOPDD. There were 
significant differences in sex, educational level, duration of Parkinsonism, and 
duration of cognitive impairment between the EOPDD and LOPDD groups. K-
MMSE score tended to be higher in the EOPDD group (19.9) than the LOPDD 
group (18.5), which may be due to the difference in age. Levodopa equivalent dose
and vascular risk factors, such as hypertension, diabetes mellitus, or dyslipidemia,
did not differ between the EOPDD and LOPDD groups. The UPDRS motor score
was higher in patients with LOPDD (35.5) than EOPDD (28.8, p=0.005). 
The demographic characteristics of 65 patients with available MRI data were 
similar to those of patients with PDD (Table 2). Mean age at onset in these 65 
patients was 64.6 years in the EOPDD group and 75.3 years in the LOPDD group. 
No significant differences in sex, MMSE, educational level, PD duration, levodopa 
equivalent dose, UPDRS motor score, or duration of memory complaints were 
observed between the EOPDD and LOPDD groups. Total intracranial volume was 
not statistically different between the two patient groups (p=0.596).
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Table 1. Demographic characteristics between patients with EOPDD and 
LOPDD
Variables EOPDD
(n=39)
LOPDD
(n=77)
p-value
Age(years) 64.6(4.3) 75.5(4.2) < 0.001
Sex (number of men, %) 18(46.2%) 37(48%) 0.847
K-MMSE 19.9(3.9) 18.5(4.8) 0.135
Education (years) 6.6(4.1) 7.8(5.5) 0.297
Parkinsonism 
duration(months)
73.5(51.8) 64.9(49.2) 0.351
Cognitive impairment 
duration (months)
6.6(4.1) 7.8(5.5) 0.209
UPDRS part III 28.8(13.5) 35.5(14.1) 0.005
Levodopa equivalent dose
(mg)
658.8(422.0) 650.8(442.9) 0.710
Hypertension 13(33.3%) 33(42.9%) 0.322
Diabetes mellitus 5(12.8%) 16(20.8%) 0.293
Dyslipidemia 2(5.1%) 2(2.6%) 0.480
Values expressed as mean (standard deviation) or number (percentage).
EOPDD: Early onset Parkinson’s disease dementia, LOPDD: Late onset Parkinson’s 
disease dementia, K-MMSE: Korean version of the Mini Mental State Examination, 
UPDRS: unified PD rating scale.
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Table 2. Demographic characteristics between patients with EOPDD and 
LOPDD (with MRI)
Variables EOPDD
(n=25)
LOPDD
(n=40)
p-value
Age(years) 64.5(4.0) 74.7(4.5) < 0.001
Sex (number of men, %) 10 (40.0%) 20 (50.0%) 0.431
K-MMSE 20.0(3.7) 18.3(4.4) 0.098
Education (years) 5.6(3.7) 7.1(5.5) 0.180
Parkinsonism 
duration(months)
55.3(33.9) 57.8(44.3) 0.814
Cognitive impairment 
duration (months)
16.4(14.5) 22.6(19.2) 0.176
UPDRS part III 31.8(13.2) 33.9(13.0) 0.545
Levodopa equivalent dose
(mg)
610.1(481.4) 723.6(385.7) 0.299
Hypertension 9(36.0%) 13(32.5%) 0.772
Diabetes mellitus 3(12.0%) 9(22.5%) 0.288
Dyslipidemia 0(0%) 0(0%) 1.0
Total intracranial 
volume(ml)
1670.3(58.5) 1670.6(63.8) 0.596
Values expressed as mean (standard deviation) or number (percentage).
EOPDD: Early onset Parkinson’s disease dementia, LOPDD: Late onset Parkinson’s 
disease dementia, K-MMSE: Korean version of the Mini Mental State Examination, 
UPDRS: unified PD rating scale.
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2. Neuropsychological features of the YOPDD and LOPDD  
The NPI score in patients with PDD is shown in Table 3. The total NPI scores and 
the subitem scores did not differ significantly between the EOPDD and LOPDD 
groups. The neuropsychological test results of patients with EOPDD and LOPDD 
are shown in Table 4. Compared with the young control group, EOPDD patients 
showed significantly poorer performances in all domains of attention, language, 
visuospatial, and memory functions. Additionally, the LOPDD group showed a 
lower score in all cognitive subdomains compared with the old control group. The 
results of a direct comparison between the EOPDD and LOPDD groups in terms of
an interaction between diagnosis and age are illustrated in Table 5. Significant 
group-by-age interaction effects were observed for backward and forward digit span 
test (p=0.05 and 0.011, respectively) and visual recognition memory function
(p=0.02) in EOPDD patients compared with LOPDD patients. In addition, EOPDD 
patients tended to show poorer performance in phonemic generative naming, 
contrasting program, and verbal memory tests (p=0.095, 0.078, and 0.118, 
respectively) than the LOPDD patients, although the difference was not statistically 
significant. No significant interaction effects between EOPDD and LOPDD groups 
were observed in language, visuospatial function, or other frontal-executive 
functions. 
The group-by-age interaction effects in the PDD subpopulation with available MRI
data are illustrated in Table 6. Similar to the overall PDD patients, significant 
group-by-age interaction effects were observed for backward digit span and visual
recognition memory tests (p=0.006 and 0.005, respectively) in EOPDD patients 
compared with LOPDD patients.
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Table 3. Analysis of neuropsychiatric inventory between patients with EOPDD 
and LOPDD
EOPDD(n=24) LOPDD(n=48) p-value
Delusion 1.1(2.5) 1.2(2.8) 0.86
Hallucination 0.8(2.5) 1.7(3.0) 0.22
Agitation/Aggression 1.2(2.9) 1.8(2.6) 0.39
Depression/Dysphoria 2.8(2.0) 2.0(2.7) 0.25
Anxiety 1.7(2.8) 2.0(3.2) 0.64
Elution/euphoria 0.3(1.2) 0.3(1.7) 0.95
Apathy/indifference 3.0(3.6) 3.7(4.0) 0.49
Disinhibition 0.5(1.4) 0.5(1.7) 0.88
Irritability/lability 2.2(3.8) 2.2(3.8) 0.99
Aberrant behavior 2.0(3.5) 1.5(3.2) 0.60
Sleep behavior 2.7(4.4) 2.9(3.9) 0.85
Appetite/eating change 1.8(3.3) 2.2(3.2) 0.58
Total score 20(22.1) 22.1(21.7) 0.70
Values expressed as mean (standard deviation)
EOPDD: Early onset Parkinson’s disease dementia LOPDD: Late onset Parkinson’s 
disease dementia
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Table 4. Neuropsychological characteristics between patients with EOPDD and LOPDD
Domain Test EOPDD LOPDD
Patients
(n=39)
Control
(n=49)
p Patients
(n=77)
Control
(n=72)
p
Attention Forward digit span 4.9(1.2) 6.8(1.5) <0.001 5.0(1.2) 6.0(1.2) <0.001
Backward digit span 2.1(1.1) 4.3(1.4) <0.001 2.2(1.3) 3.4(1.0) <0.001
Letter cancellation (error, %) 18(46.1%) 0(0%) <0.001 37(48.0%) 3(4.2%) <0.001
Language K-BNT 31.6(8.4) 50.0(5.9) <0.001 27.4(10.8) 43.6(8.7) <0.001
Visuospatial
functions
Interlocking pentagon (error, %)
RCFT
23(59.0%)
16.0(9.2)
1(2.0%)
34.4(2.7)
<0.001
<0.001
51(66.2%)
13.6(10.3)
8(11.1%)
32.5(4.8)
<0.001
<0.001
Memory Verbal 
memory
SVLT (Delayed recall)
SVLT (recognition)
1.4(1.6)
16.7(3.0)
7.0(1.7)
21.4(1.5)
<0.001
<0.001
1.1(1.6)
15.7(3.1)
5.6(1.7)
20.9(1.6)
<0.001
<0.001
Visual 
memory
RCFT (delayed recall)
RCFT (recognition)
4.1(3.9)
16.8(2.6)
17.0(5.1)
20.1(1.7)
<0.001
<0.001
2.6(3.7)
15.2(2.6)
14.0(6.1)
20.0(2.7)
<0.001
<0.001
Frontal
executive
functions
Phonemic generative
Semantic generative
Contrasting program 
Go-no-Go
Color stroop
6.3(6.2)
17.0(8.3)
13.9(7.5)
10.2(6.8)
31.9(27.3)
29.8(11.7)
35.6(8.0)
20.0(0.2)
19.5(1.8)
93.9(18.2)
<0.001
<0.001
<0.001
<0.001
<0.001
6.1(6.4)
14.8(7.2)
10.8(8.4)
8.7(7.9)
28.4(26.4)
24.0(9.5)
31.2(7.8)
19.5(1.2)
18.9(2.7)
80.9(19.0)
<0.001
<0.001
<0.001
<0.001
<0.001
Values expressed as mean (standard deviation) or number (percentage).
K-BNT: Korea version of the Boston Naming Test; RCFT: Rey Complex Figure Test; SVLT: Seoul Verbal Learning Test
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Table 5. Comparison of neuropsychological test between EOPDD and LOPDD 
patients using the group-by-age interaction effects
Domain Test P of 
interaction on 
ANCOVA
Attention Forward digit span 0.050
Backward digit span 0.011
Letter cancellation 0.554
Language K-BNT 0.950
Visuospatial Interlocking pentagon
RCFT
0.653
0.211
Memory Verbal memory SVLT (Delayed recall)
SVLT (recognition)
0.118
0.315
Visual memory RCFT (delayed recall)
RCFT (recognition)
0.722
0.002
Frontal-Executive Phonemic generative
Semantic generative
Contrasting program 
Go-no-Go
Color stroop
0.095
0.524
0.078
0.436
0.326
K-BNT: Korea version of the Boston Naming Test; RCFT: Rey Complex Figure Test;
SVLT: Seoul Verbal Learning Test
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Table 6. Comparison of neuropsychological test between EOPDD and LOPDD 
patients using the group-by-age interaction effects(with MRI)
Domain Test P of 
interaction on 
ANCOVA
Attention Forward digit span 0.172
Backward digit span 0.009
Letter cancellation 0.150
Language K-BNT 0.540
Visuospatial Interlocking pentagon
Rey copy test
0.842
0.072
Memory Verbal memory HVLT (Delayed recall)
HVLT (recognition)
0.599
0.140
Visual memory REY (delayed recall)
REY (recognition)
0.802
0.006
Frontal-Executive COWAT(A)
COWAT(S)
Phonemic generative
Semantic generative
Contrasting program
Go-no-Go
Color stroop
0.403
0.658
0.892
0.470
0.153
0.509
0.614
K-BNT: Korea version of the Boston Naming Test; RCFT: Rey Complex Figure Test;
SVLT: Seoul Verbal Learning Test
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3. Cortical thickness analysis between the EOPDD and LOPDD groups
A comparison of EOPDD patients and age-matched controls is shown in Figure 1. 
As expected, patients with EOPDD exhibited a cortical thinning in extensive 
cortical areas, involving frontal, temporal, and parietal areas. A comparison of
LOPDD and age-matched controls is shown in Figure 2. The LOPDD group showed
significant cortical thinning in widespread cortical areas of frontal, temporal, and 
parietal areas, with prominent cortical thinning in bilateral prefrontal areas. Notably, 
the areas of cortical thinning were more extensive in LOPDD than EOPDD patients. 
A direct comparison of cortical thickness between the EOPDD and LOPDD groups 
based on interaction effect demonstrated that, compared with LOPDD patients, 
EOPDD patients exhibited cortical thinning in the left anterior cingulate gyrus and a 
small area of the right mesial temporal lobe when adjusting for age with a threshold 
of uncorrected p<0.001 (Figure 3). 
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Figure 2. Analysis of cortical thickness between EOPDD patients and age-matched 
controls. The EOPDD group showed significant cortical thinning in the left 
frontoparietal and right parietotemporal areas. Additionally, cortical thinning was 
observed in the bilateral mesial temporal and left posterior cingulate areas. The 
colored areas indicate statistically significant cortical thinning in EOPDD patients
compared with controls (FDR p<0.05).
EOPDD, early-onset Parkinson’s disease dementia; FDR, false discovery rate
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Figure 3. Analysis of cortical thickness between LOPDD patients and age-matched 
controls. The LOPDD group showed significantly widespread cortical thinning in 
the bilateral frontotemporal area, particularly in the bilateral prefrontal cortex. The 
colored areas indicate statistically significant cortical thinning in LOPDD patients
compared with controls (FDR p<0.05).
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Figure 4. Analysis of cortical thickness using ANCOVA between EOPDD and 
LOPDD groups after adjusting for age. Colored areas indicate statistical 
significance. Significant group-by-age interaction was observed in the left anterior 
cingulate gyrus and right medial temporal lobe.
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4. Comparison of SI volume between the EOPDD and LOPDD groups
The mean normalized SI volumes among groups are shown in Table 7. Compared
with the young control group, the mean normalized SI volume (nSI) was 
significantly decreased in EOPDD patients (p<0.001). In LOPDD patients, nSI was 
decreased compared to the control group, although the difference was not
statistically significant. A significant group-by-age interaction effect was observed, 
suggesting that SI volume was decreased in the EOPDD group after adjusting for 
the aging effect (p=0.044).
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Table 7. Comparison of volumes of substantia innominata between EOPDD 
and LOPDD patients using the group-by-age interaction effects
EOPDD LOPDD P of 
interactionPatients
(n=25)
Control
(n=39)
p-value Patients
(n=40)
Control
(n=52)
p-value
Normalized
SI volume
6.76
(1.11)
7.81
(0.79)
<0.001 6.47
(1.58)
6.80
(0.90)
0.212 0.044
Values expressed as mean (standard deviation).
EOPDD: Early onset Parkinson’s disease dementia, LOPDD: Late onset Parkinson’s disease 
dementia
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IV. DISCUSSION
The present study demonstrated for the first time that EOPDD patients had a poorer 
cognitive performance on attention and visual recognition memory tests after
adjusting for aging effects compared with LOPDD patients. In addition, an analysis 
of cortical thickness and SI volume between the EOPDD and LOPDD groups based 
on interaction effect showed that EOPDD patients exhibited cortical thinning in the
left anterior cingulate gyrus and a small area of the right mesial temporal lobe as 
well as a smaller SI volume than the LOPDD patients. Our data suggest that 
EOPDD patients exhibit poorer cognitive performance and more severe atrophy in 
the cortex and SI compared with LOPDD patients, implying that pathological 
burden responsible for dementia in PD patients is greater in EOPDD patients.  
A comprehensive neuropsychological test showed that EOPDD patients had poorer 
performance on attention tests compared with LOPDD patients. Importantly, 
attention is a hallmark of PD-related cognitive dysfunction; thus, underlying 
impaired attention in PD is a key factor contributing to the development of 
cognitive fluctuation, visual hallucinating, frontal executive dysfunction, or 
visuospatial dysfunction.3,28 Impaired attention has also been associated with a more 
rapid cognitive decline in patients with PD.3 In terms of neuroanatomical correlates, 
the cholinergic system arising from the SI is closely associated with attention in 
patients with PD.29,30 Results have shown that the SI undergoes degeneration in the 
early stages of PD,31 with its volume being a significant predictor of PDD,32 and 
patients with PDD have a profound cholinergic deficit compared with PD patients 
without cognitive deficits.5 In the present study, the EOPDD group showed a 
significant volume reduction in the SI compared with the LOPDD group, which 
may be associated with attention deficits in the EOPDD patients. 
In addition, patients with EOPDD demonstrated cortical thinning in the anterior 
cingulate gyrus compared with LOPDD patients. Neural substrates of attention 
control are extensive networks of regions that include prefrontal and parietal 
cortices,33 superior colliculus,34 posterior parietal cortex,35 and cingulate cortex.36 Of 
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those, the anterior cingulate gyrus is reciprocally connected with frontoparietal 
regions implicated in cognitive control and maintenance of goals.37 37 Particularly, 
the anterior cingulate gyrus plays a role in identifying the motivational relevance of 
extrapersonal events and in sustaining the level of effort needed for execution of 
attentional tasks,38,39 thus being a critical component of an integrated network for 
modulation of directed attention. Taken together, these results suggest that greater 
atrophy in the SI and the anterior cingulate gyrus is possibly due to increased 
pathological burden in EOPDD compared with LOPDD and may lead to attention 
deficits in EOPDD patients. 
We also found that EOPDD patients showed poorer performance on visual 
recognition memory tests. The mesial temporal structures are required to recognize 
previously encountered items.40 Additionally, recent studies highlights the role of 
striatum and prefrontal cortex on memory retrieval.41 In patients with Alzheimer’s 
disease, a neuroimaging study showed that poor retrieval performance is related to 
decreased connectivity between parahippocampal regions and frontal areas.42 In 
terms of neuroanatomical correlates, the present study results suggest that cortical 
thinning patterns involving the right temporal area observed in patients with 
EOPDD compared with LOPDD may be attributed to visual recognition memory 
dysfunction.
In cortical thickness analysis, the EOPDD and LOPDD groups showed cortical 
thinning in bilateral frontotemporoparietal areas compared with controls; however, 
the LOPDD group showed more widespread cortical thinning involving entire
cortical areas, more significantly in the prefrontal cortex. Considering the extent of 
cortical thinning in the LOPDD group compared with controls, the major 
contributor of cortical thinning between the EOPDD and LOPDD patients is the
aging process. This is consistent with a previous study of cortical thinning in aging, 
showing prominent prefrontal thinning and relative sparing of temporal and 
parahippocampal cortices.43  
When adjusting aging effect, our analysis revealed that the EOPDD group 
exhibited a significant cortical thinning in left anterior cingulate gyrus and right 
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medial temporal areas as well as smaller SI volume relative to the LOPDD group. 
Interestingly, these areas seem to be one of key areas vulnerable to the development
of dementia in PD. Previous neuroimaging study showed non-demented patients 
with PD showed more accelerated rate of cortical thinning in bilateral fronto-
temporal areas compared to controls, which represent early PD-related degenerative 
changes.44 Hanganu et al showed PD-mild cognitive impairment(MCI) group 
exhibited increased atrophy and changes of local surface area in the bilateral 
occipital, left temporal, and frontal cortices; whereas the PD non-MCI group 
exhibited only unilateral thinning and decreased surface area in the occipital lobe 
and in the frontal cortex.45 Functional neuroimaging study also showed demented 
PD patients showed significant perfusion decrements in all cortical areas, whereas 
non-demented PD cohorts showed reductions limited to the frontal lobe area.46
Accordingly, these results imply that pathologic substrate related to cognitive 
decline in PDD may exhibit a unique spreading of cortical thinning pattern 
involving fronto-temporal areas. 
Moreover, a longitudinal neuroimaging study demonstrated that cortical thinning in 
anterior cingulate areas and the superior frontal area is a significant baseline 
predictor of development of dementia.47 Additionally, our previous study 
demonstrated that the baseline volume of the SI is a significant predictor of PDD.6
Accordingly, these results imply that anatomical correlates related to development
of dementia in patients with PD may exhibit a similar contribution to the 
development of EOPDD. However, considering that posterior cortical atrophy or 
hypometabolism is also an important factor in PDD,1,4 posterior cortical lobe-based 
pathologies may exert minimal influence on EOPDD.
Many pathologic studies investigated chronological changes of PD-related 
pathologies. Braak and colleagues proposed that caudorostral progression of Lewy 
body/Lewy neurites are linked to cognitive dysfunction in subset of patients with 
PDD.48,49 According to this scheme, the development of dementia is inevitable in 
final stage of PD. However, recent studies showed that the incidence and the 
severity of PDD are largely variable among the patients, and a portion of PD 
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patients even remain non-demented.50 Pathologic heterogeneity among the patients 
with PDD may contribute to the clinical heterogeneity of PDD in terms of 
chronological aspects. Majority of pathologic studies pointed out that cortical Lewy 
bodies are the best pathological correlates of dementia in PD.51,52 On the other hand, 
other investigators argued that only small portion of patients with cortical Lewy 
body showed clinical symptoms of dementia, suggesting alpha-synuclein-positive 
structures are not definite markers of neuronal dysfunction.53 Especially, concurrent 
Alzheimer’s disease (AD) pathology appears to be significantly correlated with 
moderate to severe dementia and negatively correlated with survival.54 Moreover, 
combination of Lewy body pathology and AD pathology was suggested to be a 
better neuropathological correlate of PDD than any of the pathologies in isolation,55
and combined AD pathology was closely associated with faster progression to 
dementia in PD.56 Importantly, Irwin et al,52 recently showed that a large number of 
PDD patients demonstrated AD pathologies at a higher correlation with older age in
PD, suggesting that LOPDD patients are at greater risk of comorbid AD. 
Subsequently, comorbid AD in EOPDD patients may be less of a risk and not solely
a consequence of PD pathological burden. A future study using clinicopathological
correlation in patients with earlier cognitive dysfunction would advance the 
understanding of pathobiology of cognitive decline in PD patients.
This study had several limitations. First, this study was not based on autopsy-proven 
data; thus, we cannot draw a solid conclusion regarding pathological substrates 
responsible for EOPDD. Second, in cortical thickness analysis, significant clusters 
were observed using a relatively liberal threshold; therefore, we could not exclude 
the possibility of false positives. This might be partly due to the small sample size 
of EOPDD patients, and other imaging analyses used to evaluate microstructural 
abnormality or functional network changes with a large sample size are warranted 
to resolve this issue. Third, due to this study’s cross-sectional design, a longitudinal 
change in cognitive performance between the EOPDD and LOPDD groups is 
lacking. 
29
V. CONCLUSION
Our data showed that EOPDD patients had severe cognitive deficit on attention 
and visual cognitive memory tests and cortical thinning in anterior cingulate and 
temporal areas compared with LOPDD patients. Additionally, SI volume was 
significantly decreased in the EOPDD group, which is correlated with attentional 
and cognitive deficits in this patient group. These results imply that PD-related 
pathological burden responsible for dementia in PD patients may be greater in 
EOPDD patients. 
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ABSTRACT(IN KOREAN)
조발성 파킨슨병치매와 만발성 파킨슨병치매 환자에서의
신경인지검사 및 대뇌피질 두께 변화에 대한 후향적 비교연구
<지도교수 이필휴>
연세대학교 대학원 의학과
김영광
파킨슨병 환자에서의 치매 발생에 있어 고령이 위험인자임은 잘 알려져
있으나, 연령에 따른 변화가 파킨슨병치매 환자들에서 신경인지검사 소견
및 병리학적 소견에 어떤 영향을 미치는지는 아직도 불확실하다. 본
저자들은 116명의 파킨슨병치매 환자와 121명의 정상인지기능을 가진
대조군을 70세를 기준으로 2개의 군으로 나누어 후향적 비교연구를
실시하였다. 39명의 환자는 70세 미만이었으며(조발성 파킨슨병치매 군), 
77명의 환자는 70세 이상이었다. (만발성 파킨슨병치매 군) 모든 환자에서
신경인지검사를 시행하였다. 65명의 환자에서 3차원 고해상도 T1 강조
자기공명영상을 시행하였으며, 상기 환자군에서 대뇌피질두께에 대한
비교분석 및 대뇌 무명질에 대한 부피분석을 시행하였다. 통계분석을
위하여 연령 및 성별보정을 시행한 121명의 정상 인지기능인 대조군을
구하였다. 신경인지검사 결과와 대뇌피질두께, 무명질 부피는 질병
여부와 연령, 그리고 두 변수간의 상호작용이 있는지를 공분산분석으로
분석하였으며, 교육 수준과 고혈압, 당뇨, 고지혈증의 변수를 공변량으로
설정하였다. 두 군 사이에서 성별, 간이인지기능검사 점수, 교육 수준, 
파킨슨병 유병기간, 레보도파 용량 및 기억력 감소 증상의 기간에 있어서
통계적으로 유의한 차이는 없었으며, 만발성 파킨슨병 치매 환자에서
통합된 파킨슨병 평가 점수는 유의하게 낮은 수치를 보였다. 
신경인지검사상에서 언어 능력, 시공간 능력, 전두엽 집행기능 영역에서
두 군 사이의 유의한 차이는 없었다. 그러나 나이를 보정하였을 때
거꾸로 따라 외우기 (p=0.011), 시각재인검사에서 (p=0.002)
조발성파킨슨병치매 환자군이 유의하게 낮은 수행능력을 보임을 알 수
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있었다. 대뇌피질두께 분석상에서 좌측 전대상피질과 우측 중앙
측두엽에서 나이를 보정했을 때 조발성파킨슨병치매에서 대뇌피질의
두께가 얇아졌음을 알 수 있었다. 또한 나이를 보정하였을 때
조발성파킨슨병치매 환자에서 무명질 부피의 감소가 관찰되었다. 이러한
결과는 조발성파킨슨병치매 군에서 인지기능의 악화와 관련된 영역의
병리학적 변화가 더 심하다는 것을 시사하며, 만발성파킨슨병치매
군에서는 연령변화와 관련된 비교적 광범위한 병리학적 변화를 보임을
시사한다. 본 연구는 두 질병군에서 다른 치료적 접근이 필요함을 보여
주는 결과로 사료된다.
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